title: Tegaserod in constipation associated with Parkinson disease.
abstract: Impaired gastrointestinal motility and constipation are common problems in Parkinson disease (PD). Many patients with PD continue to experience constipation, despite multiple interventions (dietary modification, bulk-forming agents, stool softeners, and laxatives). Tegaserod is a 5-hydroxytryptamine type 4 agonist that stimulates gastrointestinal motility and is approved for the treatment of chronic idiopathic constipation. We report our experience with tegaserod in 5 patients with PD-associated constipation. Tegaserod was well tolerated and improved both bowel movement frequency and stool consistency in most of our patients. Further trials with tegaserod are warranted in PD-associated constipation.
authors.affiliation: Movement Disorders Program, National Parkinson Foundation Center of Excellence, Department of Neurology, Medical College of Georgia, Augusta, GA, USA. jmorgan@msg.edu
authors.forename: John C
authors.initials: JC
authors.lastname: Morgan
authors.forename: Kapil D
authors.initials: KD
authors.lastname: Sethi
mesh_terms: D000368:Aged; D002908:Chronic Disease; D003248:Constipation / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*
chemical_list: D007211:Indoles; D017366:Serotonin Receptor Agonists; C105050:tegaserod